Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1332196 | 0.87 | THRB (0.38) | THRB | |
| SCHEMBL5822752 | 0.86 | THRB (0.55) | THRBUSP2CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL2150236 | 0.83 | THRB (0.52) | THRBALDH1A1LMNA | |
| SCHEMBL13496631 | 0.82 | THRB (0.50) | THRBALDH1A1LMNA | |
| SCHEMBL6036653 | 0.81 | THRB (0.43) | THRBLMNA | |
| SCHEMBL6434584 | 0.81 | THRB (0.38) | THRBLMNA | |
| SCHEMBL11167716 | 0.81 | THRB (0.43) | THRB | |
| SCHEMBL1888683 | 0.81 | THRB (0.62) | THRBUSP2CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL25949401 | 0.81 | THRB (0.62) | THRBUSP2CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL1491969 | 0.80 | THRB (0.50) | THRBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304604-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | TOPIKOS SCIENTIFIC, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-12180239-B2 | Organosilanes for the treatment of infections | TOPIKOS SCIENTIFIC, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20210253607-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | TOPIKOS PHARMACEUTICALS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| WO-2020082026-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | TOPIKOS PHARMACEUTICALS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253607-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | ASNS, ACMSD, ARG1 | THRB 4843/4885USP2 489/4885CYP3A4 804/4885 |
| US-12180239-B2 | Organosilanes for the treatment of infections | ASNS, ACMSD, ARG1 | THRB 4843/4885USP2 489/4885CYP3A4 804/4885 |
| US-20250304604-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | ASNS, ACMSD, ARG1 | THRB 4843/4885USP2 489/4885CYP3A4 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.